Your AI-Trained Oncology Knowledge Connection!

Bhumika Patel, MD

Articles

Tagraxofusp in BPDCN: Practical Advice and Future Directions in Care

Thomas W. LeBlanc, MD, MA;Bhumika Patel, MD

January 12th 2023

After sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.

Addressing Myelosuppression While Managing BPDCN With Tagraxofusp

Thomas W. LeBlanc, MD, MA;Bhumika Patel, MD

January 12th 2023

Before closing out their review of adverse events associated with tagraxofusp, Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on the identification and management of myelosuppression.

BPDCN Management: Tagraxofusp as a Bridge to Stem Cell Transplant

Thomas W. LeBlanc, MD, MA;Bhumika Patel, MD

January 5th 2023

A brief review of the role of tagraxofusp as bridging therapy to stem cell transplant in patients diagnosed with blastic plasmacytoid dendritic cell neoplasm.

Tagraxofusp in BPDCN: Optimizing the Management of Adverse Events

Thomas W. LeBlanc, MD, MA;Bhumika Patel, MD

January 5th 2023

Comprehensive discussion on the management of adverse events associated with tagraxofusp and how BPDCN care can be optimized in the setting of academic centers.

Long-Term Efficacy Data of Tagraxofusp in the 1L Management of BPDCN

Thomas W. LeBlanc, MD, MA;Bhumika Patel, MD

December 22nd 2022

Centering discussion on a recent study, experts Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on long-term data with tagraxofusp in BPDCN.

An Overview on Blastic Plasmacytoid Dendritic Cell Neoplasm and Tagraxofusp Therapy

Thomas W. LeBlanc, MD, MA;Bhumika Patel, MD

December 22nd 2022

Expert hematologist-oncologists share their perspective on the broad diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN).